| Cost-effectiveness analysis of the MiniMed 670G hybrid closed-loop system versus continuous subcutaneous insulin infusion for treatment of type 1 diabetes J Jendle, J Pöhlmann, S de Portu, J Smith-Palmer, S Roze Diabetes Technology & Therapeutics 21 (3), 110-118, 2019 | 51 | 2019 |
| Mixture cure models in oncology: a tutorial and practical guidance F Felizzi, N Paracha, J Pöhlmann, J Ray PharmacoEconomics-open 5, 143-155, 2021 | 32 | 2021 |
| Cost-effectiveness of physical activity interventions in cancer survivors of developed countries: a systematic review BE Gubler-Gut, J Pöhlmann, A Flatz, M Schwenkglenks, S Rohrmann Journal of Cancer Survivorship, 1-15, 2021 | 23 | 2021 |
| Liraglutide versus lixisenatide: long-term cost-effectiveness of GLP-1 receptor agonist therapy for the treatment of type 2 diabetes in Spain P Mezquita-Raya, A Ramirez de Arellano, N Kragh, G Vega-Hernandez, ... Diabetes Therapy 8, 401-415, 2017 | 18 | 2017 |
| Is the EUnetHTA HTA Core Model® fit for purpose? Evaluation from an industry perspective M Gyldmark, K Lampe, J Ruof, J Pöhlmann, A Hebborn, FB Kristensen International journal of technology assessment in health care 34 (5), 458-463, 2018 | 16 | 2018 |
| Nasal glucagon versus injectable glucagon for severe hypoglycemia: a cost-offset and budget impact analysis J Pöhlmann, BD Mitchell, S Bajpai, B Osumili, WJ Valentine Journal of Diabetes Science and Technology 13 (5), 910-918, 2019 | 15 | 2019 |
| Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs K Grabe-Heyne, C Henne, P Mariappan, G Geiges, J Pöhlmann, ... Frontiers in Oncology 13, 1170124, 2023 | 13 | 2023 |
| Treating patients with type 2 diabetes mellitus uncontrolled on basal insulin in the Czech Republic: cost-effectiveness of IDegLira versus iGlarLixi J Pöhlmann, M Russel-Szymczyk, P Holík, K Rychna, B Hunt Diabetes Therapy 10, 493-508, 2019 | 13 | 2019 |
| Value for money in the treatment of patients with type 2 diabetes mellitus: assessing the long-term cost-effectiveness of IDegLira versus iGlarLixi in Italy J Pöhlmann, R Montagnoli, G Lastoria, W Parekh, M Markert, B Hunt ClinicoEconomics and Outcomes Research, 605-614, 2019 | 11 | 2019 |
| Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy J Pöhlmann, K Norrbacka, KS Boye, WJ Valentine, H Sapin The European Journal of Health Economics 21 (8), 1179-1196, 2020 | 10 | 2020 |
| A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric … NA Kennedy, MM Achebe, P Biggar, J Pöhlmann, RF Pollock International Journal of Clinical Pharmacy 45 (3), 604-612, 2023 | 4 | 2023 |
| Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose S Hu, L Liu, RF Pollock, J Pöhlmann, D Wu, Y Zhang Journal of Medical Economics 25 (1), 561-570, 2022 | 4 | 2022 |
| Biosimilars in der Schweiz: Medizin gegen die steigenden Gesundheitskosten? I Kobler, G Lenzin, F Liberatore, J Pöhlmann, M Schmidt, S Wieser ZHAW Zürcher Hochschule für Angewandte Wissenschaften, 2020 | 3 | 2020 |
| PDB77-LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN … R Montagnoli, G Lastoria, W Parekh, J Pöhlmann, B Hunt Value in Health 21, S131, 2018 | 2 | 2018 |
| PDB75-COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS … C Hvid, W Parekh, J Pöhlmann, B Hunt Value in Health 21, S131, 2018 | 2 | 2018 |
| Nasal Glucagon Saves Professional Emergency Medical (EM) Costs Versus Intramuscular Glucagon—A Us Based Cost-Offset Model S Bajpai, J Poehlmann, B Osumili, B Mitchell, WJ Valentine Value in Health 21, S76, 2018 | 2 | 2018 |
| Disutilities associated with intravenous iron infusions: results from a time trade-off survey and diminishing marginal utility model for treatment attributes in China S Hu, D Wu, J Wu, Y Zhang, M Bøgelund, J Pöhlmann, RF Pollock Patient Related Outcome Measures, 253-267, 2023 | 1 | 2023 |
| HSD114 Reductions in Travel Time and Carbon Dioxide Emissions Arising From Patient Transportation to Hospitals in England for Treatment With Intravenous Iron: An Analysis … W Ahmed, J Pöhlmann, S Brewerton, J Sørensen, M Nottmeier, ... Value in Health 25 (12), S295, 2022 | 1 | 2022 |
| High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma J Pöhlmann, M Weller, A Marcellusi, K Grabe-Heyne, L Krott-Coi, S Rabar, ... Frontiers in Oncology 14, 1368606, 2024 | | 2024 |
| Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK K Grabe-Heyne, C Henne, I Odeyemi, J Pöhlmann, W Ahmed, RF Pollock Journal of Medical Economics 26 (1), 411-421, 2023 | | 2023 |
Richard F PollockCovalence Research LtdVerified email at covalence-research.com
